Clinician fact sheet : Virologic and immunologic characteristics of severe mpox in persons with advanced HIV (VIRISMAP)

Details

• Corporate Authors:
  National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of High-Consequence Pathogens and Pathology.
• Description:
  Updated April 20, 2023
  
  People with advanced HIV who contract mpox are at risk of severe illness and death. The extent to which the pathology of mpox in patients with advanced HIV is driven by mpox viral effects versus a dysregulated immune response – and potentially immune reconstitution inflammatory syndrome (IRIS) – is unclear. CDC is collaborating with the National Institutes of Health (NIH) to study the extent of mpox viral spread and immunologic markers in people with advanced HIV.
  
  Findings from this study will enhance knowledge of mpox pathogenesis in severely immunocompromised people, which can inform treatment and prevention of severe illness and deaths associated with mpox in people with advanced HIV. The study will include people living in the United States who are at least 18 years old and who have HIV with CD4 count < 200 cells/mL and are hospitalized with probable or confirmed mpox.
  
  
• Subjects:
  HIV Infections/complications Mpox (monkeypox)/complications
• Document Type:
  Webpage
• Collection(s):
  Stephen B. Thacker CDC Library
• Main Document Checksum:
  urn:sha256:d538698a551b3afe9f0e6c433dd4855fa11495317779c4c7fc6d7e8b40d7ddac
• Download URL:
  https://stacks.cdc.gov/view/cdc/127337/cdc_127337_DS1.pdf
• File Type:
  [PDF - 239.90 KB ]